my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
09-13-2010: Basilea Pharmaceutica Ltd. announces that Janssen-Cilag AG, a Johnson & Johnson company, will be discontinuing sale of ceftobiprole (Zevtera(TM)) for the treatment of complicated skin and soft tissue infections (cSSTI) in Switzerland.
Janssen-Cilag AG, the holder of the Marketing Authorization in Switzerland, has requested Swissmedic to withdraw the marketing authorization of Zevtera(TM) and will discontinue sale of Zevtera(TM) as of September 17, 2010. This action is being taken based on the unfavorable assessments of the marketing authorization applications for ceftobiprole in the United States and the European Union.
Physicians are advised to allow all patients on Zevtera(TM) to complete their course of therapy and not to initiate treatment of new patients. Zevtera(TM) was authorized in Switzerland in November 2008 for the treatment of cSSTI. There have been no safety observations that would be in conflict with the approved label of Zevtera(TM).
The decision to discontinue sale of the product in the Swiss market does not preclude the submission of a new application for marketing authorization in the future.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Basilea Pharmaceutica Ltd. announced that it will apply in the second half of 2012 for approval of its antibiotic ceftobiprole in Europe. In addition, reporting of topline data for the alitretinoin U.S. phase III study for chronic refractory hand eczema will occur in the first quarter of th ... more
Basilea appoints Chief Financial Officer
Basilea Pharmaceutica Ltd. announced that Joachim Blatter has been appointed Chief Financial Officer (CFO) of Basilea Pharmaceutica International Ltd.Joachim Blatter will join Basilea mid-January 2012 as Chief Financial Officer and member of the management committee. In addition to finance ... more
Basilea announces change in its management structure
Basilea Pharmaceutica Ltd. announced that Ronald Scott has been appointed Chief Operating Officer (COO) of Basilea Pharmaceutica International Ltd.Ronald Scott was appointed Chief Financial Officer at the company's inception. In addition to finance, business development, investor relations ... more
Johnson & Johnson Acquires 98.89% of Issued Crucell Shares
Johnson & Johnson and Crucell N.V. announced that following the end of the subsequent offering period (na-aanmeldingstermijn, Subsequent Offering Period), Johnson & Johnson has acquired 98.89% of the issued Shares in Crucell N.V. (Crucell) (which includes treasury shares held by Crucell) an ... more
Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional
Johnson & Johnson and Crucell N.V. announced that Johnson & Johnson has completed the tender offer for Crucell N.V. (Crucell) and has declared the offer unconditional. As a result, Crucell will now operate as the center for vaccines within the Johnson & Johnson pharmaceuticals group.Refere ... more
Johnson & Johnson Launches Recommended Public Offer to Acquire Crucell
Johnson & Johnson and Crucell N.V. announced that Johnson & Johnson, through its newly formed indirect wholly owned subsidiary, JJC Acquisition Company B.V. (the Offeror), is making a recommended cash offer for all of the issued and outstanding ordinary shares (Ordinary Shares) in the capi ... more
Swissmedic, the Swiss Agency for Therapeutic Products, and the Australian Therapeutic Goods Administration (TGA) have granted approval for Gilenya® (fingolimod) 0.5 mg as a first-line, oral disease-modifying therapy (DMT) for the treatment of relapsing-remitting multiple sclerosis (RRMS)."G ... more
Discontinuation of sale of ceftobiprole in Switzerland
Basilea Pharmaceutica Ltd. announces that Janssen-Cilag AG, a Johnson & Johnson company, will be discontinuing sale of ceftobiprole (Zevtera(TM)) for the treatment of complicated skin and soft tissue infections (cSSTI) in Switzerland. Janssen-Cilag AG, the holder of the Marketing Authoriza ... more
Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna is the first new therapeutic option for newly diagnosed patients ... more
Discontinuation of sale of ceftobiprole in Switzerland
Basilea Pharmaceutica Ltd. announces that Janssen-Cilag AG, a Johnson & Johnson company, will be discontinuing sale of ceftobiprole (Zevtera(TM)) for the treatment of complicated skin and soft tissue infections (cSSTI) in Switzerland. Janssen-Cilag AG, the holder of the Marketing Authoriza ... more
European CHMP concludes re-examination of ceftobiprole
Basilea Pharmaceutica Ltd. announces that following a request for re-examination from the Applicant Janssen-Cilag International NV, a Johnson & Johnson company, the European Committee for Medicinal Products for Human Use (CHMP) confirmed its previous negative opinion on the Marketing Author ... more
European CHMP adopts negative opinion on ceftobiprole
Basilea Pharmaceutica Ltd. announced that the European Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on the Marketing Authorization Application (MAA) for ceftobiprole for the treatment of complicated skin and soft tissue infections (cSSTI). The sponsor Jan ... more
Janssen-Cilag develops and markets innovative, high-quality pharmaceutical products and services aimed at improving quality of life for people with medical needs across the world. We view ourselves as a full-service partner for all stakeholders in healthcare, as evidenced in the first line ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
